摘要
胰岛功能障碍是2型糖尿病的重要发病机制之一,是2型糖尿病治疗的重要靶点,而现有治疗手段保护β细胞功能作用有限。最新的研究发现,基于肠促胰素的药物包括胰高血糖素样肽-1(glucagon-like peptide-1,GLP-1)受体激动剂及二肽基肽酶-4(dipeptidyl peptidase-4,DPP-4)抑制剂,不仅能够改善β细胞功能,而且能够避免低血糖、体重增加等不良反应,是治疗2型糖尿病的新途径。
Islet dysfunction is one of the important pathogenesis of type 2 diabetes, is one of the important targets for type 2 diabetes treatment, and treatment to protect existing beta cell function. The latest study found that, based on the bowel to promote pancreatic hormone drugs including sample glucagon peptide 1 （glueagon - like peptide 1, glp-1） agonists and dipeptide based peptidase - 4 （dipeptidyl peptidase 4, DPP - 4） inhibitor, can not only improve β-cell function, but also reduce adverse reactions such as to avoid hypoglycemia, weight gain, thus it is a new way for the treatment of type 2 diabetes.
出处
《药品评价》
CAS
2016年第7期33-37,56,共6页
Drug Evaluation
